Alexza Pharmaceuticals Inc (NASDAQ:ALXA)

CAPS Rating: 1 out of 5

An emerging pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions.

Recs

2
Player Avatar zzlangerhans (99.77) Submitted: 1/3/2013 2:32:17 AM : Underperform Start Price: $5.09 ALXA Score: +11.27

The Alexza excitement is over now that approval in both the US and Europe was met with a trans-Atlantic loud yawn. The commercial potential of Adasuve is highly questionable and the company will almost certainly dilute ahead of launch. As an ER doc, the very idea of a mask inhalation sedative for an agitated patient seems ridiculous to me. Everything else I hear about the specs such as the necessity of patient compliance with the treatment and the duration of the treatment just make it sound worse. I think unless Alexza can come up with a follow up act to Adasuve, they're likely headed to the same fate as Labopharm. Remember Labopharm?

Featured Broker Partners


Advertisement